Abstracts tagged "Biologics and abatacept"

Abstract Number: 1431 • 2013 ACR/ARHP Annual Meeting
Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Mitsuyoshi Iwahashi³, Tomomi Tsuru⁴, Shoichi Uchimura⁵, Shigeru Honjo⁶, Akira Sagawa⁷, Takeo Sakurai⁸, Hiroaki Matsuno⁹, Tomomaro Izumihara¹⁰, Eisuke Shono¹¹, Kou Katayama¹², Toyomitsu Tsuchida¹³ and Motohiro Oribe¹⁴, ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ⁴PS Clinic, Fukuoka, Japan, ⁵Kanzaki Municipal General Hospital, Kanzaki, Japan, ⁶Honjo Rheumatism Clinic, Takaoka, Japan, ⁷Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁸Inoue Hospital, Takasaki, Japan, ⁹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ¹⁰Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ¹¹Shono Rheumatology Clinic, Fukuoka, Japan, ¹²Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ¹³Tsuchida Clinic, Chiba, Japan, ¹⁴Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Abatacept (ABT), a CTLA4-Ig fusion protein agent targeted to T-cells, is a relatively new biological agent for RA treatment in Japan. However, there is…